Page last updated: 2024-12-11

pardoprunox

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pardoprunox: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918525
CHEMBL ID2103832
SCHEMBL ID805311
MeSH IDM0550671

Synonyms (43)

Synonym
du-126891
7-(4-methylpiperazin-1-yl)-3h-benzooxazol-2-one
L001636
D09397
pardoprunox (usan/inn)
7-(4-methylpiperazin-1-yl)-3h-1,3-benzoxazol-2-one
269718-84-5
5r72chp32s ,
du 126891
2(3h)-benzoxazolone, 7-(4-methyl-1-piperazinyl)-
unii-5r72chp32s
slv 308
7-(4-methylpiperazin-1-yl)-1,3-benzoxazol-2(3h)-one
pardoprunox [usan:inn]
pardoprunox
CHEMBL2103832
slv308
pardoprunox [inn]
du126891
pardoprunox [who-dd]
pardoprunox [usan]
YVPUUUDAZYFFQT-UHFFFAOYSA-N
SCHEMBL805311
CS-4378
7-(4-methyl-1-piperazinyl)-2(3h)-benzoxazolone
7-[(4-methyl)-1-piperazinyl]-2(3h)-benzoxazolone
HY-14958
J-690276
AKOS026750201
EX-A624
pardoprunox (slv308)
DB12061
FT-0700276
BCP17731
Q27882143
pardoprunox free base
269718-84-5 (free base)
F17400
mfcd19443755
slv-308;du-126891
7-(4-methylpiperazin-1-yl)benzo[d]oxazol-2(3h)-one
DTXSID40949747
AC-36807

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" However, once dyskinesia has developed, dopamine agonists administered with l-dopa exacerbate involuntary movements."( The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Jackson, MJ; Jenner, P; McCreary, AC; Rose, S; Tayarani-Binazir, K, 2010
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's8 (72.73)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.86 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (45.45%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (45.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]